Mortgage rates fall, providing some relief to home buyers
By Aarthi Swaminathan
U.S. mortgage rates tick down amid spring homebuying season
Mortgage rates tick down, offering home buyers some relief in terms of affordability.
The 30-year fixed-rate mortgage fell and averaged 6.79% as of March 28, according to data released by Freddie Mac (FMCC) on Thursday.
It's down 8 basis points from the previous week - one basis point is equal to one hundredth of a percentage point.
A year ago, the 30-year was averaging at 6.32%.
The average rate on the 15-year mortgage was 6.11%, down from 6.21% last week. The 15-year was at 5.68% a year ago.
Freddie Mac's weekly report on mortgage rates is based on thousands of applications received from lenders across the country that are submitted to Freddie Mac when a borrower applies for a mortgage.
Separate data by Mortgage News Daily said that the 30-year fixed-rate mortgage was averaging at 6.91% as of Thursday afternoon. The Mortgage Bankers Association's survey noted that the 30-year was at 6.93% as of March 22.
What Freddie Mac said: "Rates remain elevated near seven percent as markets watch for signs of cooling inflation, hoping that rates will come down further," Sam Khater, chief economist at Freddie Mac, said in a statement.
-Aarthi Swaminathan
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
03-28-24 1201ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth